瑞舒伐他汀对代谢综合征患者血清血管生成素-2和超敏C反应蛋白的影响

目的观察瑞舒伐他汀对代谢综合征（MS）患者血清血管生成素-2（Ang-2）和超敏C反应蛋白（hs-CRP）的影响及其安全性。方法将80例MS患者分为治疗组40例和对照组40例。两组均给予降压治疗，同时治疗组加用瑞舒伐他汀10mg／d口服，疗程8周。对照组不用任何调脂药。治疗前和治疗后8周分别检测血清Ang-2、hs-CRP浓度及肝、肾功能，比较两组治疗前、后各相关指标的差异。结果（1）治疗组治疗8周后Ang-2和hs-CRP浓度较治疗前显著降低（1．81±0．47）μg／L降至（0．30±0．01）μg／L，（6．32±1．28）mg／L降至（2．02±0．26）mg／L；t=9．02、t=5．75，P均〈0．01]；而对照组上述指标在治疗前后比较差异均无统计学意义（1．80±0．45）μg/L与（1．79±0．48）μg／L，（6．28±1．34）mg／L与（6．20±1．42）mg／L；t=0．19、t=0．23，P均〉0．05]。（2）治疗8周后治疗组的Ang-2和hs-CRP浓度与对照组相比明显降低（0．30±0．01）μg／L与（1．79±0．48）μg／L，（2．02±0．26）mg／L与（6．20±1．42）mg／L；t=2．34、t=2．58，P均〈0．05]。（3）治疗组不良反应少，安全性好。结论瑞舒伐他汀可降低MS患者血清Ang-2和hs-CRP浓度，改善胰岛素抵抗，其安全性良好。

The impact of rosuvastatin on serum Ang-2 and hs-CRP in patients with metabolic syndrome

Objective To observe the impact of rosuvastatin on serum Ang-2 and hs-CRP in patients with metabolic syndrome （MS） to collect data on safety of rosuvastatin in treating MS. Methods Eighty MS patients were enrolled and divided into the treatment group （ n = 40 ） and the control group （ n = 40 ） . The treatment group received both antihypertensive therapy and rosuvastatin with a dose of 10 mg/d. While the control group were only given antihypertensive therapy and but not any lipid-lowering drugs. The levels of plasma Ang-2 and hs-CRP and liver and kidney functions were measured and compared before and after 8-week treatment. Results （1） The levels of plasma Ang-2 and hs-CRP were significantly lower after 8 weeks than before treatment in the treatment groups Ang-2 ： （ 0. 30 ± 0. 01 ） μg/L vs. （ 1.81 ± 0. 47 ） μg/L, t = 9.02, P 〈 0. 01 ;hs-CRP： （ 2.02 ± 0. 26 ） mg,/L vs. （ 6. 32 ± 1.28 ） mg/L, t = 5.75, P 〈 0.01 ] . Whereas statistical difference was not found in the control group Ang-2 ： （ 1.80 ± 0.45 ） μg/L vs. （ 1.79 ± 0. 48 ） μg/L, t = 0. 19, P 〉0. 05 ;hs-CRP： （6. 28 ± 1.34 ） mg/L vs. （ 6. 20 ± 1.42 ） mg/L, t = 0. 23, P 〉 0.05 ]. （ 2 ） After 8 weeks＇ treatment, the levels of plasma Ang-2 and hs-CRP were significantly lower in the treatment group than in the control group Ang-2 ： （0. 30 ± 0. 01 ） μg/L vs. （ 1.79 ± 0. 48）μg/L, t = 2. 34, P 〈 0. 05 ; （2. 02 ± 0. 26） mg/L vs. （6. 20 ± 1.42）mg/L,t = 2. 58 ,P 〈 0.05 ]. （3）The adverse reaction in the treatment group was fewer than the control group and the security of rosuvastatin treatment on MS was fine. Conclusion Rosuvastatin can reduce plasma Ang-2 and hs-CRP levels and improve insulin resistance in patients with MS. Its security is fine.